NCT05370287Recruiting
Adaptive Optics Retinal Imaging
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 19 Apr 2022
- Start date
- 22 Jan 2018
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Food and Drug Administration (FDA)
- Diseases
- Glaucoma
- NCT number
- NCT05370287
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 22 Jan 2018 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
- Have a history of adverse reaction to mydriatic drops.
- Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
- Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only).
- Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.
Age
- Are under 21 years of age.
Other
- Have visual correction outside of the range +4 diopters (D) to -8 D.
- Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)
- Have a dependency on oxygen support or a baseline oxygen saturation \<95% (RBF experiment participants only).
- Are working under the direct supervision of Dr. Hammer.
Who the study is looking for
- Are 21 years of age or older.
- Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
- Have the ability to understand and sign an informed consent.
- Have been diagnosed with POAG (cohort 2).
Age in the registry: 21 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Food and Drug Administration Coordinator of this site? Confirm its status | Silver Spring | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.